Surgery to remove deep brain bleeding with urokinase
Part of Brain & nervous system clinical trials.
This trial tests whether a targeted (stereotactic) procedure to remove deep brain bleeding, combined with a medicine called urokinase, is safer and works better than standard care. It focuses on people whose bleeding is in the deep brain and who are able to undergo surgery within a specific time window.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 40 or older
- Your brain scan (CTA) was done 6 to 24 hours after symptoms started
- The bleeding is from spontaneous (not caused by injury or known vessel problem) deep brain tissue, and the bleed is bigger than 25 mL
- Your initial awareness level score (GCS) is between 9 and 15
- You have some new movement weakness (motor deficit) and were fully independent before the bleed (mRS 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a minimally invasive procedure to remove deep brain bleeds using a special puncture guided by brain imaging, combined with a clot-dissolving drug called tenecteplase. It may help reduce damage from the bleed and improve recovery.
This trial tests whether a minimally invasive brain surgery using an endoscope can improve outcomes for people with a deep brain bleed. It also studies the safety of this approach compared with standard care.
This trial tests a minimally invasive surgery to remove blood clots deep in the brain after a spontaneous bleed. It may help patients with moderate to large bleeds who are at least 18 and up to 80 years old.
This trial tests whether using a small camera and a tube to very quickly remove a brain bleed through a tiny hole in the skull improves recovery compared to standard medical care. It is for people who have a large, non-traumatic brain hemorrhage and can have surgery within a few hours of the bleed.
This trial tests a minimally invasive surgery to remove blood clots deep in the brain caused by spontaneous bleeding. It aims to improve recovery for patients who meet specific criteria, such as clot size and time since symptoms started.
This trial studies whether a special scan-guided, minimally invasive procedure can safely remove bleeding in the basal ganglia (deep in the brain) soon after it happens. It may help patients recover better by targeting the bleeding while protecting important brain pathways.
Hear when a new Treatment of Spontaneous Intracerebral Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.